Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.51 |
| ▸ | PDE4A | P27815 | 5/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945670 | 0.89 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DPDCD1 | |
| SCHEMBL4944690 | 0.87 | PDE5A (0.53) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL4942500 | 0.85 | MAPT (0.48) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL4937419 | 0.83 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DPDCD1 | |
| SCHEMBL4937823 | 0.81 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DPDCD1 | |
| SCHEMBL4944537 | 0.81 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DPDCD1 | |
| SCHEMBL4943052 | 0.81 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DPDCD1 | |
| SCHEMBL4937607 | 0.80 | MAPT (0.54) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20138653 | 0.79 | GAA (0.48) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL4943065 | 0.77 | HTT (0.57) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE5A | PDE4B 2/4885PDE4A 1/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.